Drug Delivery Systems
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
206
NCT06662877
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Phase: Phase 2/3
Role: Collaborator
Start: Nov 25, 2024
Completion: Sep 1, 2029
Loading map...